Publication date: Jun 01, 2024
Most reported adverse events following COVID-19 vaccination have been transient. However, persistent adverse events may occur with some frequency. This study aimed to analyze patient background characteristics and trends, with a focus on whether adverse events following COVID-19 vaccination were transient or persistent. A retrospective study was performed at a single institution in Japan. The study cohort included 47 patients who presented with symptoms after COVID-19 vaccination between May 2021 and September 2023. The patients were classified into two groups based on the duration of symptoms: transient group, less than four weeks; persistent group, greater than or equal to four weeks. Data on age, sex, body mass index, smoking history, underlying conditions, type of COVID-19 vaccination, number of doses, onset, symptoms, and treatments were collected retrospectively. The median age was 51. 0 years and 74. 5% were females, with a particularly high proportion of women in their 40s. The use of the bivalent omicron-containing booster vaccine (BA. 1) was significantly more common in the persistent group than in the transient group (p = 0. 0267). Onset in the transient group was more common after the first vaccination, whereas onset in the persistent group was more common after the second and subsequent vaccinations (p = 0. 003). Regarding symptoms, pain was more frequent in the persistent group than in the transient group (60% vs. 13. 6%; p = 0. 001). This study investigated the presence of persistent symptoms, especially pain, after COVID-19 vaccination. Persistent symptoms were frequently reported after the second vaccination. It should be noted that the study does not negate the usefulness of COVID-19 vaccines.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Fourweeks | covid-19 |
| Japan | covid-19 vaccines |
| Pain | persistent symptoms |
| Vaccinations | post covid-19 vaccination |
| Women | transient symptoms |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | VO | vaccination |
| disease | VO | frequency |
| drug | DRUGBANK | Aspartame |
| disease | IDO | history |
| disease | VO | vaccine |
| drug | DRUGBANK | Coenzyme M |
| disease | VO | immunization |
| disease | VO | effective |
| disease | MESH | emergency |
| disease | VO | adverse event |
| disease | VO | population |
| disease | IDO | country |
| disease | VO | vaccine adverse event |
| disease | MESH | polymyalgia rheumatica |
| disease | MESH | malignant lymphoma |
| disease | MESH | brain tumor |
| disease | VO | age |
| disease | VO | vaccination dose |
| disease | MESH | hypertension |
| disease | MESH | psychiatric disorders |
| disease | VO | dose |
| disease | IDO | symptom |
| disease | VO | time |
| disease | IDO | site |
| drug | DRUGBANK | Zinc |
| drug | DRUGBANK | Iron |
| drug | DRUGBANK | Folic Acid |
| disease | MESH | subacute thyroiditis |
| disease | VO | vaccinated |
| disease | MESH | back pain |
| drug | DRUGBANK | Acetaminophen |
| disease | VO | vaccine effectiveness |
| disease | MESH | Thrombosis |
| disease | MESH | thrombocytopenia |
| disease | MESH | liver diseases |
| disease | MESH | syndrome |
| disease | MESH | IgA nephropathy |
| drug | DRUGBANK | Rosiglitazone |
| disease | VO | prime boost regimen |